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Despite the recent global spread of CTX-M β-lacta-
mases in Escherichia coli isolates from community-ac-
quired urinary tract infections (CA-UTIs), their dissemina-
tion has been little studied in developing countries. In a 
2-year prospective study, we documented the prevalence 
of extended-spectrum β-lactamases (ESBLs) in E. coli that 
were responsible for CA-UTIs in Phnom-Penh, Cambodia. 
Ninety-three  E. coli strains were included. We observed 
a high prevalence of resistance to amoxicillin (88.2% of 
strains), cotrimoxazole (75.3%), ciproﬂ  oxacin  (67.7%), 
gentamicin (42.5%), and third-generation cephalosporins 
(37.7%). A total of 34 strains carried ESBLs, all of which 
were CTX-M type. CTX-M carriage was associated with 
resistance to ﬂ   uoroquinolones and aminoglycosides. Us-
ing repetitive extragenic palindromic–PCR, we identiﬁ  ed 4 
clusters containing 9, 8, 3, and 2 strains. The prevalence of 
CTX-M β-lactamases has reached a critical level in Cam-
bodia, which highlights the need for study of their spread in 
developing countries.
E
scherichia coli is the bacterium most frequently isolat-
ed in community- and hospital-acquired urinary tract 
infections (CA-UTIs and HA-UTIs, respectively). Despite 
possessing the gene encoding cephalosporinase, ampC (1), 
wild strains of E. coli are susceptible to most β-lactams be-
cause of the absence of an efﬁ  cient ampC promoter region. 
The extensive use of β-lactam antimicrobial drugs has led 
to the emergence of resistant strains worldwide. β-lactam 
resistance is mostly mediated through acquisition of 
β-lactamase genes located on mobile genetic elements such 
as plasmids or transposons. Most β-lactamases found in E. 
coli belong to Ambler class A and can be further divided 
into narrow-spectrum β-lactamases (e.g., TEM-1, TEM-2, 
and SHV-1) and extended-spectrum β-lactamases (ESBLs) 
(e.g., TEM-3, SHV-5, and CTX-M-like) (1–3). ESBLs con-
fer resistance to extended-spectrum cephalosporins, widely 
used to treat E. coli infections.
CTX-M–type β-lactamases (CTX-Ms) are broad-spec-
trum β-lactamases derived from the chromosomally encod-
ed β-lactamases of Kluyvera sp. (4–6). So far, >70 CTX-M 
types have been isolated (www.lahey.org/studies, updated 
October 2008); these have been divided into 5 clusters on 
the basis of amino acid sequence: CTX-M-1, CTX-M-2, 
CTX-M-8, CTX-M-9, and CTX-M-25. Native CTX-Ms 
are cefotaximases that usually hydrolyze cefotaxime rather 
than ceftazidime. However, point mutations can extend 
their target spectrum to ceftazidime. Thus, CTX-M-15 and 
CTX-M-27 are derived by a single Asp240Gly substitution 
from CTX-M-3 and CTX-M-14, respectively (7,8).
Until recently, most ESBLs in clinical samples came 
from a hospital environment, belonged to the TEM or SHV 
β-lactamase family, and were produced by Klebsiella spp., 
Enterobacter spp., and E. coli (9). Within the past few years, 
the nature of ESBL dissemination has changed: E. coli is 
now the most frequently isolated ESBL-carrying bacteri-
um, and CTX-Ms have become the most frequently isolated 
ESBLs (10). Moreover, in the last few years CTX-M–type 
ESBLs have emerged within the community, particularly 
among E. coli isolated from UTIs (11–16). Risk factors for 
CTX-M carriage in the community are largely unknown. 
CTX-Ms have been isolated from patients with CA-UTIs 
who have neither had recent antimicrobial drug treatment 
nor been admitted to a hospital or long-term-care facility 
(17–19). Resistance to ﬂ  uoroquinolones, aminoglycosides, 
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and cotrimoxazole is often associated with CTX-M produc-
tion (16,17), thereby limiting the choice of effective anti-
microbial drugs to carbapenems or colistin.
Some studies have shown high prevalence of ESBLs 
among various Enterobacteriaceae in hospitals in develop-
ing countries (20–22). However, little information is avail-
able regarding prevalence within the community. Few bac-
teriologic data are available for Cambodia, and no studies 
of resistance of Enterobacteriaceae to antimicrobial agents 
have been reported. We investigated E. coli CA-UTIs in 
a 2-year prospective study. Our aims were 1) to establish 
the prevalence of community-acquired urinary E. coli re-
sistance to a wide range of antimicrobial drugs and 2) to 
characterize the mechanisms underlying E. coli resistance 
to β-lactams. 
Methods
Clinical Isolates from Patient Samples
Our laboratory at the Institut Pasteur in Phnom Penh, 
Cambodia, is a community laboratory, involved in various 
biological analyses. We receive biological samples from 
outpatients and hospitals that do not have bacteriology lab-
oratories. Included in the study were patients who visited 
our laboratory with a suspected UTI from January 2004 
through December 2005. Currently hospitalized patients 
were excluded, yet previous hospitalization was not an 
exclusionary criterion. We collected basic clinical data for 
each patient, including age and gender, whether antimicro-
bial drugs had been taken within the month preceding the 
sample submission, UTI history, and recent hospital visit. 
A UTI was deﬁ  ned by >104 leukocytes/mL urine and >105 
CFU/mL urine. We used CLED (cystine-lactose-electrolyte 
deﬁ  cient) agar (Dynamic Pharma, Phnom-Penh, Cambo-
dia) for culture. Bacteria were identiﬁ  ed with the API20E 
identiﬁ  cation gallery (bioMérieux, Marcy l’Etoile, France). 
Strains were named (CEC [Cambodian Escherichia coli]) 
and numbered independently from isolation date.
Antimicrobial Drug Susceptibility Testing and ESBL 
Conﬁ  rmatory Testing
We determined antimicrobial drug susceptibility by 
the disk-diffusion method on Mueller-Hinton agar plates 
(Bio-Rad, Marnes-la-Coquette, France), as recommended 
by the French Society for Microbiology (www.sfm.asso.
fr). We tested the following antimicrobial agents: amoxi-
cillin, amoxicillin/clavulanic acid (coamoxiclav), ticarcil-
lin, ticarcillin/clavulanic acid, piperacillin, piperacillin/
tazobactam, cefalothin, cefoxitin, cefotaxime, ceftazidime, 
cefepime, imipenem, moxalactam, aztreonam, nalidixic 
acid, norﬂ  oxacin, ciproﬂ  oxacin, gentamicin, tobramycin, 
netilmicin, amikacin, nitroxolin, fosfomycin, and sulfame-
thoxazole/trimethoprim (cotrimoxazole). We detected ES-
BLs by using the double-disk synergy test (clavulanic acid 
and cefotaxime, ceftazidime, cefepime and aztreonam) 
performed on Mueller-Hinton media. We determined MICs 
for cefoxitin, cefotaxime, ceftazidime, and cefepime by us-
ing the agar-dilution method for ESBL-carrying strains and 
strains with decreased susceptibility to cefoxitin (as inter-
preted by the disk-diffusion method) as recommended by 
the French Society for Microbiology. For cefoxitin, strains 
were considered susceptible if MICs were <8 mg/L; inter-
mediate susceptible if MICs were 16–32 mg/L, and resis-
tant if MICs were >32 mg/L. For cefotaxime, strains were 
considered susceptible if MICs were <1 mg/L; intermedi-
ate susceptible if MICs were 2 mg/L, and resistant if MICs 
were >2 mg/L. For ceftazidime and cefepime, strains were 
considered susceptible if MICs were <4 mg/L, intermedi-
ate susceptible if MICs were 8 mg/L, and resistant if MICs 
were >8 mg/L.
PCR Ampliﬁ  cations
Template DNA was prepared by boiling. Brieﬂ  y, 5 
colonies were suspended thoroughly in 1 mL DNase- and 
RNase-free water and boiled for 10 min. After centrifuga-
tion, supernatant was used as template DNA. We ampli-
ﬁ  ed the ampC upstream region, blaTEM, blaSHV, blaCTX-M, 
blaVEB, blaOXA-1, and blaCMY by PCR, using speciﬁ  c oligode-
oxynucleotides (Table 1). PCR was performed in a 25-μL 
mixture of 1× buffer (supplied with Taq polymerase), 2.5 
mmol/L MgCl2, 2.5 U of FIREPol DNA polymerase (Solis 
BioDyne, Tartu, Estonia), 200 μmol/L of each deoxynucle-
oside triphosphate, and 25 pmol of each primer. The PCR 
mixture was subjected to a 5-min denaturation step at 94°C, 
followed by 30 cycles of 45 s at 94°C, 45 s at 55°C, and 60 
s at 72°C, and a ﬁ  nal elongation step of 5 min at 72°C. PCR 
products were separated by 100-V electrophoresis in a 2% 
agarose gel for 30 min, after which they were stained with 
ethidium bromide.
PCR Product Sequencing 
Ampliﬁ  cation products were puriﬁ  ed with Montage 
PCR Filter Units (Millipore, Billerica, MA, USA). Se-
quencing reactions were performed in a PTC-225 Peltier 
Thermal Cycler (MJ Research, Waltham, MA, USA) by 
using an ABI PRISM BigDye Terminator Cycle Sequenc-
ing Kit with AmpliTaq DNA polymerase (Applied Biosys-
tems, Branchburg, NJ, USA), according to the manufac-
turer’s instructions. Each template was sequenced with the 
appropriate primer. Fluorescence-labeled fragments were 
puriﬁ  ed from the unincorporated terminators with an etha-
nol precipitation protocol. The samples were resuspended 
in distilled water and subjected to electrophoresis in an ABI 
3730xl sequencer (Applied Biosystems).
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Phylogenetic Group Determination
To determine phylogenetic group (i.e., A, B1, B2, and 
D), we performed triplex PCR for all strains (n = 93) as 
described previously (29). We used chuA and yjaA genes 
and an E. coli DNA fragment, TSPE4.C2.
Repetitive Extragenic Palindromic PCR
The clonality of ESBL-positive strains was assessed 
by repetitive extragenic palindromic (rep)–PCR. DNA 
was extracted by using the QIAGEN Mini kit (QIAGEN, 
Courtaboeuf, France). REP-PCRs were performed for all 
strains in the same batch with primers rep-1R and rep-2T, 
as described previously (28). The resulting products were 
separated by 70-V electrophoresis in a 1% agarose gel for 
3 h, after which they were stained with ethidium bromide. 
Strains with suspected similar migration proﬁ  les were then 
migrated together with the ESBL-positive strains to assess 
their similarity. Photographs of the gels (Figure) have been 
harmonized to be more informative.
Statistical Analysis
Data were analyzed by using Epi Info version 3.2 
(www.cdc.gov/epiinfo). Risk factors for ESBL-producing 
E. coli were assessed by using univariate analysis with 
the χ2 or Fisher exact tests; however, we used analysis of 
variance to determine whether age had an association with 
ESBL-producing E. coli. Associations between ESBL type, 
co-resistance, mutations in ampC promoter regions, and 
phylogenetic groups were separately tested by using the χ2 
or Fisher exact tests. The signiﬁ  cance threshold was 0.05.
Results
Population Characteristics
Of the 861 urine samples, 194 were positive for UTI 
and 163 contained E. coli.  Samples from hospitalized pa-
tients and samples isolated from the same patient in a short 
period were excluded from the study. Overall, 93 patients 
with E. coli–related CA-UTIs were recruited for the study, 
all of whom were living in Phnom Penh. Their mean age 
was 43 years (range 1–88 years, median 40 years), and the 
M:F ratio was 0.21. No pregnant women were included. 
Twenty-eight (30.1%) patients had a history of UTI (with 
no details available), 24 (25.8%) had taken antimicrobial 
drugs, and 9 (9.7%) had sought consultation at a hospital 
in the month preceding the urine sampling. Patients with a 
history of UTI had taken signiﬁ  cantly more antimicrobial 
drugs than had persons without UTIs (p<0.0001).
Prevalence of Antimicrobial Drug Resistance in E. coli 
Strains
Disk-diffusion susceptibility testing indicated high 
prevalence of resistance to various antimicrobial agents: 88 
(94.6%) strains were resistant to amoxicillin and ticarcillin, 
and 20 (21.5%) were immediate susceptible to cefoxitin. 
We observed synergy between clavulanic acid, oxyimino-
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Table 1. Primers used to study CTX-M ȕ-lactamases in Escherichia coli, Cambodia, 2004–2005 
Gene detected  Primer name  Primer sequence (5ƍ ĺ 3ƍ) Reference 
blaTEM C  TCG GGG AAA TGT GCG CG 
D  TGC TTA ATC AGT GAG GCA CC 
(23) 
blaSHV OS-5  TTA TCT CCC TGT TAG CCA CC 
OS-6  GAT TTG CTG ATT TCG CTC GG 
(24) 
blaCTX-M MA-1  SCS ATG TGC AGY ACC AGT AA 
MA-2  CCG CRA TAT GRT TGG TGG TG 
(23) 
blaCTX-M group 9 M9U  ATG GTG ACA AAG AGA GTG CA 
M9L  CCC TTC GGC GAT GAT TCT C 
(23) 
blaCTX-M group 1 M13U  GGT TAA AAA ATC ACT GCG TC 
M13L  TTG GTG ACG ATT TTA GCC GC 
(23) 
blaampC AmpC1  AAT GGG TTT TCT ACG GTC TG 
AmpC2  GGG CAG CAA ATG TGG AGC AA 
(25) 
blaVEB casF  CGA CTT CCA TTT CCC GAT GC 
casB  GGA CTC TGC AAC AAA TAC GC 
(26) 
blaOXA-1 OXA-1up  TAT CAA CTT CGC TAT TTT TTT A 
OXA-1low  TTT AGT GTG TTT AGA ATG GTG A 
(27) 
blaCMY CF1 ATGATGAAAAAATCGTTATGC 
CF2 TTGTAGCTTTTCAAGAATGCGC 
(28) 
chuA ChuA.1  GAC GAA CCA ACG GTC AGG AT 
ChuA.2  TGC CGC CAG TAC CAA AGA CA 
(29) 
ygaA YgaA.1  TGA AGT GTC AGG AGA CGC TG 
YgaA.2  ATG GAG AAT GGG TTC CTC AAC 
(29) 
TspE4C2 TspE4C2.1  GAG TAA TGT CGG GGC ATT CA 
TspE4C2.2  CGC GCC AAC AAA GTA TTA GC 
(29) RESEARCH
cephalosporins, and aztreonam for 34 strains (36.6%). De-
creased susceptibility to cefoxitin was signiﬁ  cantly associ-
ated with ESBL expression (p<0.001). All strains (n = 93) 
were susceptible to imipenem. One strain (CEC93) showed 
a high level of resistance to cefoxitin, cefotaxime, and cef-
tazidime but not to cefepime; double-disk synergy test re-
sults were negative for clavulanate. We observed a substan-
tial level of resistance to quinolones; 63 strains (67.7%) had 
an intermediate level of resistance or were fully resistant to 
nalidixic acid, norﬂ  oxacin, and ciproﬂ  oxacin. Quinolone 
resistance was strongly associated with ESBL expression 
(p<0.0001). Of the 34 ESBL-carrying strains, only 2 were 
susceptible to quinolones. Cotrimoxazole resistance was 
observed in 70 strains (75.3%) but was not signiﬁ  cantly as-
sociated with ESBL expression (p = 0.06). Aminoglycoside 
resistance was also signiﬁ  cantly associated with ESBL ex-
pression (p<0.01). Thirty-nine strains (41.9%) were resis-
tant to at least 1 of the 4 tested aminoglycosides. The most 
frequently observed phenotypic proﬁ  le included resistance 
to gentamicin, tobramycin, and netilmicin (37.6% of the 
strains). None of the strains were resistant to fosfomycin or 
nitrofurantoin (Table 2).
Risk Factors for ESBL Carriage
Univariate analysis showed no risk factors for ESBL 
carriage. Carriage was not signiﬁ  cantly associated with gen-
der, age, previous hospitalization (within the past month), 
antimicrobial drug treatment (within the last month), or his-
tory of UTI. 
β-Lactamase Characterization
Thirty-four strains were tested for ESBL identiﬁ  ca-
tion. They were all positive for blaCTX-M and negative for 
blaVEB and blaSHV. We detected blaTEM in 26 (76.4%) of the 
ESBL-carrying strains. CTX-M-14 was the most frequent-
ly isolated ESBL (n = 15), followed by CTX-M-27 (n = 
12) and CTX-M-15 (n = 5). One strain (CEC7) was carry-
ing both blaCTX-M-14 and blaCTX-M-15. Strain CEC14 was car-
rying a blaCTX-M-14 variant, which differed from the paren-
tal enzyme by a single transversion (C825G) leading to a 
Ser273Arg amino acid change. blaTEM-1 was detected in 24 
(96%) of the blaTEM-carrying strains. One strain (CEC23) 
had a DNA sequence that differed from TEM-1 by 4 nucle-
otides. Only 1 of these mutations resulted in an amino acid 
change (Met182Thr). Amino acid sequence comparison 
(www.lahey.org/studies/webt.asp) showed that this TEM 
had the same amino acid sequence as TEM-135.
Strain CEC93, exhibiting a phenotypic proﬁ  le indica-
tive of a high level of cephalosporinase expression, was 
positive for blaCMY. Sequencing conﬁ  rmed the presence of 
blaCMY-2 in this strain. We detected blaOXA-1 in 4 CTX-M-15
–producing strains: CEC15, CEC48, CEC68, and CEC89.
ampC Sequencing Results
Strains with different levels of resistance to cefoxitin, 
ranging from intermediate (cefoxitin MIC = 8 mg/L) to full 
resistance (cefoxitin MIC >8 mg/L), had different muta-
tions within the region upstream from ampC (Table 3). 
Only 1 strain did not display any mutations. Most mutations 
occurred within the transcriptional attenuator region; the 
most frequently observed proﬁ  le were +22 C>T, +26 T>G, 
+27 A>T, +32 G>A, and +70 C>T (11 strains). The other 
strains each exhibited a different proﬁ  le. Strain CEC57 had 
the proﬁ  le –32 T>A with an additional nucleotide change, 
which signiﬁ  cantly increases ampC expression (31). Strain 
CEC92 had the combination –42 C>T and –28 G>A, which 
also increases ampC expression (25).
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Figure. Results of repetitive extragenic palindromic–PCR of 
Escherichia coli isolates belonging to the 4 clusters, Cambodia, 
2004–2005. CEC, Cambodian E. coli.
Table 2. Resistance to antimicrobial agents among ESBL-positive and ESBL-negative Escherichia coli, Cambodia, 2004–2005* 
Resistance ratios, % (no. resistant strains) 
Antimicrobial agent  ESBL+, n = 34  ESBL–, n = 59  Total, n = 93  p value 
Fluoroquinolones  94 (32)  53 (31)  68 (63)  <0.001 
Cotrimoxazole  85 (29)  69 (41)  75 (70)  0.06 
Aminoglycosides  65 (22)  27 (16)  42 (39)  <0.01 
Co-amoxiclav  94 (32)  19 (11)  46 (43)  <0.001 
Cefoxitin  41 (13)  11 (7)  22 (20)  <0.001 
Nitrofurantoin 0  0  0  NS 
Fosfomycin 0  0  0  NS 
*ESBL, extended-spectrum ȕ-lactamase; NS, not significant. CTX-M β-Lactamases in E. coli
Phylogenetic Groups 
Most of the strains studied belonged to groups B2 
(53%; n = 49) and D (28%; n = 26), as do most pathogenic 
E. coli (32). Twelve strains belonged to group A (13%) and 
6 to group B1 (6%). Among ESBL-carrying strains, 53% 
belonged to group B2 (n = 18), 38% to D (n = 13), 6% to A 
(n = 2), and 3% to B1 (n = 1). Resistance to cotrimoxazole 
was less prevalent in B2 strains than among strains from 
the other groups (p<0.05). Resistance to quinolones was 
more prevalent among group D strains than in strains from 
other groups (p<0.005). Furthermore, a strong association 
(p<0.0001) was found between decreased susceptibility to 
cefoxitin and group D strains. No association was shown 
between phylogenetic group and other characteristics such 
as ESBL carriage and aminoglycoside resistance. Among 
ESBL-carrying strains, none of the 4 groups were associ-
ated with 1 particular type of CTX-M.
Rep-PCR Findings
Twenty-one ESBL positive strains and the CMY-2–
producing strain were divided into 4 clusters; the remaining 
strains were genetically unrelated (online Appendix Table, 
available from www.cdc.gov/EID/content/15/5/741-appT.
htm; Figure). Cluster C1 consisted of 8 strains with an iden-
tical ampC mutation proﬁ  le, all belonging to phylogenetic 
group D. However, β-lactamase content was variable: 6 
strains harbored CTX-M-27 and TEM-1, 1 strain harbored 
only CMY-2, and 1 harbored only CTX-M-15. Strain CEC7 
(belonging to group B2, carrying CTX-M-14 and CTX-M-
15, with no ampC mutations) exhibited a REP-PCR proﬁ  le 
similar to that of strains in cluster C1. Cluster C2 consisted 
of 8 strains belonging to group B2 with no ampC muta-
tions and carrying various β-lactamases; 6 strains produced 
CTX-M-14 (2 of which co-produced TEM-1), 1 produced 
CTX-M-27/TEM-1, and 1 produced CTX-M-15/TEM-1/
OXA-1. Cluster C3 consisted of 3 strains from group D, 
all with the same ampC mutation proﬁ  le, but with 3 distinct 
β-lactamase proﬁ  les (CTX-M-14 and TEM-1; CTX-M-14-
like and TEM-1; and CTX-M-15 and TEM-1). Cluster C4 
consisted of 2 strains from group D, each with the same 
ampC mutation proﬁ  le but different β-lactamase proﬁ  les 
(CTX-M-14 and TEM-1; and CTX-M-27 only). 
Discussion
We surveyed antimicrobial drug resistance in Cambo-
dia. Our prospective study in this developing country fo-
cused on CTX-Ms CA-UTIs caused by E. coli. Although 
the patients included came from the community, antimi-
crobial drug resistance was prevalent among UTI-causing 
strains, particularly to β-lactams (including extended-spec-
trum cephalosporins). Our ﬁ  ndings suggest that CTX-M-
type β-lactamases are widespread in Cambodia. CTX-M 
production was signiﬁ  cantly associated with resistance to 
quinolones and aminoglycosides and with decreased sus-
ceptibility to cefoxitin, leading to a high prevalence of mul-
tiresistant strains. The spread of CTX-M in the community 
has already been described through prospective studies in 
industrialized countries such as Canada (33), France (34), 
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Table 3. Mutations detected in the ampC promoter region of CTX-M ȕ-lactam–resistant Escherichia coli* 
Mutation at position† 
Isolate 
CEF MIC, 
mg/L  CTX-M 
Phylogenetic 
group  42 32 28 18 1  +22 +26 +27  +32  +58 +70 +81
E. coli K12 
(U00096)
–  –  –  C  T  G  G  C  C  T  A  G  C  C  G 
CEC1  16  Yes  D        T  G  T  A    T   
CEC3  32  No  D        T  G  T  A    T   
CEC4  32  No  D      A  T       T    
CEC6  32  Yes  D        T  G  T  A    T   
CEC8  32  Yes  D        T  G  T  A    T   
CEC9  32  Yes  D        T  G  T  A    T   
CEC10  32  Yes  D        T  G  T  A    T   
CEC13  32  Yes  D        T  G  T  A    T   
CEC14  16  Yes  D             T    
CEC15  16  Yes  D             T    
CEC19  32  No  D        T  G  T  A    T   
CEC21  16  Yes  D     A         T    A 
CEC22  16  Yes  D             T    
CEC31  16  Yes  D     A         T    A 
CEC57  32  No  D    A        T G T A    T   
CEC88  32  No  B2     A            A  
CEC89  32  Yes  D        T  G  T  A    T   
CEC92  >128  Yes  D  T     A  T       T    
CEC93  >128  No  D        T  G  T  A    T   
*CEF, cefoxitin; CEC, Cambodian E. coli. 
†According to numbering of Jaurin and Grundström (30). RESEARCH
and the United Kingdom (12); however, we found higher 
prevalence of CTX-Ms in Cambodia than that reported in 
these previous studies.
We propose 3 possible explanations for the situation 
in Cambodia. First, although no reliable data were avail-
able, it is well known that many persons in the community 
self-medicate or obtain prescriptions for non-adapted drugs 
(drugs taken without any antibiotic susceptibility testing of 
the strain that causes the infections); these practices sug-
gest that uncontrolled consumption of antimicrobial agents 
is likely to play a major role. This factor, together with 
the likely substandard quality of some drugs, undoubtedly 
contributes to the high prevalence of resistance. Second, 
hygiene in Cambodia is poor, and the population density 
in Phnom Penh is high. The saturated sewer system, par-
ticularly during the rainy season, likely facilitates efﬁ  cient 
propagation and spread of bacteria within the community. 
Grenet et al. proposed that that poor hygiene in a French-
Guyanese Indian community led to the spread of resistant 
bacteria despite low antibiotic pressure (35). Similarly, 
poor hygiene conditions may have led to the spread of re-
sistant strains in the Cambodian community studied here. 
The TEM-type and SHV-type ESBL—until recently the 
predominant ESBL family subtypes—have never been 
implicated in the spread of ESBL in the community. Why 
CTX-M strains are the only ESBL types to spread in the 
community is not clear. CTX-M strains may have a par-
ticularly high capacity to disseminate or an ecologic advan-
tage over other ESBLs and thus persist in the community, 
whereas other ESBL may be progressively eliminated with 
decreasing antibiotic pressure.
One limitation to our study is that patients at our in-
stitute are not necessarily representative of the Cambodian 
population. For most persons in Cambodia, antimicrobial 
agents and biologic analyses are expensive. Therefore, our 
patients may have been wealthier and may have taken more 
courses of antimicrobial drug treatment than other Cam-
bodians.
REP-PCR yielded 4 clusters of strains, consistent with 
their identical ampC mutational proﬁ  les, yet with various 
contents of β-lactamases. Because all included patients 
were living in Phnom Penh, mediocre hygiene might have 
favored the diffusion of clones within an urban area, a phe-
nomenon that had previously been observed in large-scale 
studies undertaken in the United Kingdom (12), Canada 
(36), Italy (37), and Brazil (15) but not in Hong Kong (13). 
In contrast to our results, clones identiﬁ  ed in those stud-
ies harbored the same β-lactamases. Further investigation 
using multilocus sequence typing would be necessary to 
identify the molecular determinants of the CTX-M–carry-
ing E. coli pandemic in Cambodia.
Branger et al. have observed that group D E. coli were 
more frequently resistant to quinolones (38) than were 
non-D E. coli; these ﬁ  ndings are consistent with our re-
sults. Moreover, we found a strong association (p<0.001) 
between group D strains and decreased susceptibility to 
cefoxitin (secondary to the effect of mutations in the ampC 
promoter region). This association was also present when 
all strains were taken into account (p<0.001). However, al-
though CTX-M carriage was more frequently observed for 
group D strains than for non-D strains, the association was 
not signiﬁ  cant. Given that quinolone resistance and ampC 
hyperexpression involve several mutations, a possible ex-
planation for this association with group D strains may be a 
stronger mutation capacity for these strains than for strains 
belonging to other groups. Further investigations will be 
required to explain this phenomenon.
Community-isolated ESBL-carrying strains are an 
emerging challenge for community practitioners and hos-
pitals. Information is not readily available in either de-
veloping countries or in industrialized countries, and UTI 
treatment guidelines remain unchanged. In Cambodia, and 
probably in many other developing countries, resistant E. 
coli strains are endemic to the community. Investigating 
the current situation in Cambodia may improve our under-
standing of the situation in industrialized countries, where 
ESBLs are no longer uncommon in the community. Ac-
cording to our experience in Cambodia, measures should 
focus on improving hygiene and appropriate prescribing 
of antimicrobial agents. In conclusion, we suggest that this 
high prevalence of β-lactam resistance in Cambodia is due 
to the intrinsic capacity of CTX-M–encoding genes to dis-
seminate through communities where hygiene and living 
conditions are poor and antimicrobial drug consumption is 
uncontrolled.
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